5 Most Undervalued Pot Stocks To Buy According To Hedge Funds

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Number of Hedge Fund Holders: 43

Forward P/E as of February 6: 9.23

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the most popular cannabis stocks among elite money managers. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a pharma company that is focusing immensely on cannabis-related products. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) made headlines in 2021 after announcing plans to buy GW Pharmaceuticals for a whopping $7.2 billion. GW is behind EPIDIOLEX, the first FDA-approved prescription cannabidiol (CBD) to treat seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC), in patients 1 year of age or older.

Insider Monkey’s database of 920 hedge funds’ holdings shows that 43 hedge funds entered into the fourth quarter of 2022 with Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares in their portfolios. The net worth of the stakes of these hedge funds was $1.2 billion. The biggest stakeholder of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) among these hedge funds was Bernard Horn’s Polaris Capital Management which owns a $196 million stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ).